(Circulation. 1999;99:620-625.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Rapid Platelet-Function Assay
An Automated and Quantitative Cartridge-Based Method
From Accumetrics, Inc, San Diego, Calif (J.W.S., J.C., T.L., R.S.H.); the Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio (S.R.S., A.M.L.); and the Department of Medicine, Mount Sinai Medical Center, New York, NY (B.S.C.).
Correspondence to Dr Barry Coller, Department of Medicine, Box 1118, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029.
Background—The platelet glycoprotein (GP) IIb/IIIa receptor is important in mediating platelet thrombus formation, and the GP IIb/IIIa antagonist abciximab (c7E3 Fab; ReoPro) is effective in preventing thrombotic ischemic cardiovascular complications of unstable angina and percutaneous coronary interventions. Small-molecule antagonists of GP IIb/IIIa based on the Arg-Gly-Asp (RGD) sequence show similar benefit, and some of these agents are orally active. However, there may be significant interindividual variation in response to such antagonists, especially with chronic oral therapy. It will be essential to balance the beneficial antithrombotic effect of these drugs with their potential for causing bleeding. In response to this need, we have developed a rapid platelet-function assay (RPFA), a point-of-care system that provides a quantitative measure of the competence of the GP IIb/IIIa receptor as reflected in the ability of platelets to agglutinate fibrinogen-coated beads.
Methods and Results—Polystyrene beads were coated with fibrinogen and placed in a cartridge along with a lyophilized peptide that activates the thrombin receptor. Anticoagulated whole blood was added to the cartridge, and then a microprocessor-controlled operation mixed the reagents and detected agglutination between platelets and coated beads. Quantitative digital results were displayed within 3 minutes. Because there is no dilution of the blood, the assay can be used to measure platelet activity in samples that have been treated with GP IIb/IIIa antagonists with high dissociation rates. RPFA results of whole-blood samples treated with different GP IIb/IIIa antagonists correlated well with both conventional turbidimetric platelet aggregation (r2=0.95) and the percentage of free GP IIb/IIIa molecules in the sample (r2=0.96). The mean difference in measurements between RPFA and aggregometry was –4% (±4% SD), and the mean difference in measurements between RPFA and free GP IIb/IIIa receptors was –2% (±6% SD).
Conclusions—The RPFA provides rapid information on platelet function that mirrors turbidimetric platelet aggregation and reflects GP IIb/IIIa receptor blockade.
Key Words: platelets • glycoproteins • drugs
This article has been cited by other articles:
 |
|
 |
|
  C. Varenhorst, S. James, D. Erlinge, J. T. Brandt, O. O. Braun, M. Man, A. Siegbahn, J. Walker, L. Wallentin, K. J. Winters, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur. Heart J., July 2, 2009; 30(14): 1744 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gachet and B. Aleil Testing antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A28 - A34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Harle Point-of-Care Platelet Function Testing Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 247 - 251. [Abstract] [PDF]
|
|
|
|
 |
|
 P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson Platelet Function Monitoring in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mahmud, J. J. Cavendish, S. Tsimikas, L. Ang, C. Nguyen, G. Bromberg-Marin, G. Schnyder, S. Keramati, V. Palakodeti, W. F. Penny, et al. Elevated Plasma Fibrinogen Level Predicts Suboptimal Response to Therapy With Both Single- and Double-Bolus Eptifibatide During Percutaneous Coronary Intervention J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2163 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Howard-Alpe, J. de Bono, L. Hudsmith, W. P. Orr, P. Foex, and J. W. Sear Coronary artery stents and non-cardiac surgery Br. J. Anaesth., May 1, 2007; 98(5): 560 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V L Serebruany, M G Midei, H Meilman, A I Malinin, and D R Lowry Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad. Med. J., June 1, 2006; 82(968): 404 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Shanmugam Tirofiban and emergency coronary surgery Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 546 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Serebruany, A. I. Malinin, W. Ziai, A. N. Pokov, D. L. Bhatt, M. J. Alberts, and D. F. Hanley Effects of Clopidogrel and Aspirin in Combination Versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Patients After Recent Ischemic Stroke: For the Plavix Use for Treatment of Stroke (PLUTO-Stroke) Trial Stroke, October 1, 2005; 36(10): 2289 - 2292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Harrison, H. Segal, K. Blasbery, C. Furtado, L. Silver, and P. M. Rothwell Screening for Aspirin Responsiveness After Transient Ischemic Attack and Stroke: Comparison of 2 Point-of-Care Platelet Function Tests With Optical Aggregometry Stroke, May 1, 2005; 36(5): 1001 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Serebruany, M. G. Midei, A. I. Malinin, B. R. Oshrine, D. R. Lowry, D. C. Sane, J.-F. Tanguay, S. R. Steinhubl, P. B. Berger, C. M. O'Connor, et al. Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study Arch Intern Med, October 11, 2004; 164(18): 2051 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M.S.K.J. Ernst, H. Suryapranata, K. Miedema, R. J. Slingerland, J. P. Ottervanger, J. C.A. Hoorntje, A.T.M. Gosselink, J.-H. E. Dambrink, M.-J. de Boer, F. Zijlstra, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1187 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brownlee Inaugural Article: Biography of Barry S. Coller PNAS, September 7, 2004; 101(36): 13111 - 13113. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. I. Lev, D. Hasdai, E. Scapa, A. Tobar, A. Assali, J. Lahav, A. Battler, J. J. Badimon, and R. Kornowski Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: Effect on platelet function and thrombus formation J. Am. Coll. Cardiol., March 17, 2004; 43(6): 966 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Reiter, F. Mayr, H. Blazicek, E. Galehr, P. Jilma-Stohlawetz, H. Domanovits, and B. Jilma Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin Blood, December 15, 2003; 102(13): 4594 - 4599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Heitzer, I. Ollmann, K. Koke, T. Meinertz, and T. Munzel Platelet Glycoprotein IIb/IIIa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease Circulation, August 5, 2003; 108(5): 536 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Lau, L. A. Waskell, P. B. Watkins, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, D. G.M. Carville, K. E. Guyer, and E. R. Bates Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug-Drug Interaction Circulation, January 7, 2003; 107(1): 32 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Bonz, B. Lengenfelder, J.o. Strotmann, S. Held, O. Turschner, K. Harre, C. Wacker, C. Waller, N. Kochsiek, M. Meesmann, et al. effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial) J. Am. Coll. Cardiol., August 21, 2002; 40(4): 662 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Palmerini, M. A. Nedelman, L. E. Scudder, M. T. Nakada, R. E. Jordan, S. Smyth, R. E. Gordon, J. T. Fallon, and B. S. Coller Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates J. Am. Coll. Cardiol., July 17, 2002; 40(2): 360 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.W.G. Leebeek, E. Boersma, C.P. Cannon, F.J.J. van de Werf, and M.L. Simoons Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable Eur. Heart J., March 2, 2002; 23(6): 444 - 457. [Full Text] [PDF]
|
|
|
|
|
|
S. Samson and L. Shore-Lesserson Platelet Function and Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2001; 5(4): 273 - 281. [Abstract] [PDF]
|
|
|
|
|
|
L. Shore-Lesserson Monitoring the Hematologic Complications of Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 207 - 216. [Abstract] [PDF]
|
|
|
|
|
|
S. R. Steinhubl, J. D. Talley, G. A. Braden, J. E. Tcheng, P. J. Casterella, D. J. Moliterno, F. I. Navetta, P. B. Berger, J. J. Popma, G. Dangas, et al. Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention : Results of the GOLD (AU-Assessing Ultegra) Multicenter Study Circulation, May 29, 2001; 103(21): 2572 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann, W. Hochholzer, G. Pogatsa-Murray, A. Schomig, and M. Gawaz Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K M Akkerhuis, M J B M van den Brand, C van der Zwaan, H O J Peels, H Suryapranata, L R van der Wieken, J Stibbe, J Hoffmann, T Baardman, J W Deckers, et al. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty Heart, April 1, 2001; 85(4): 444 - 450. [Abstract] [Full Text]
|
|
|
|
|
|
J. I. Osende, V. Fuster, E. I. Lev, D. Shimbo, U. Rauch, J. D. Marmur, M. Richard, D. Varon, and J. J. Badimon Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests : Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition Circulation, March 20, 2001; 103(11): 1488 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Akkerhuis, K.-L. Neuhaus, R. G. Wilcox, A. Vahanian, J.-L. Boland, J. Hoffmann, T. Baardman, G. Nehmiz, U. Roth, A. P. J. Klootwijk, et al. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study Eur. Heart J., December 2, 2000; 21(24): 2042 - 2055. [Abstract] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt and E. J. Topol Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA, September 27, 2000; 284(12): 1549 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Peter, B. Kohler, A. Straub, J. Ruef, M. Moser, T. Nordt, M. Olschewski, M. E. Ohman, W. Kubler, and C. Bode Flow Cytometric Monitoring of Glycoprotein IIb/IIIa Blockade and Platelet Function in Patients With Acute Myocardial Infarction Receiving Reteplase, Abciximab, and Ticlopidine : Continuous Platelet Inhibition by the Combination of Abciximab and Ticlopidine Circulation, September 26, 2000; 102(13): 1490 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Despotis and L. T. Goodnough Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery Ann. Thorac. Surg., August 1, 2000; 70(2): S20 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Bussel, T. J. Kunicki, and A. D. Michelson Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease Hematology, January 1, 2000; 2000(1): 222 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Waldmann, R. Levy, and B. S. Coller Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy Hematology, January 1, 2000; 2000(1): 394 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Nurden, C. Poujol, C. Durrieu-Jais, and P. Nurden Platelet Glycoprotein IIb/IIIa Inhibitors : Basic and Clinical Aspects Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 2835 - 2840. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Steinhubl, K. Kottke-Marchant, D. J. Moliterno, M. L. Rosenthal, N. K. Godfrey, B. S. Coller, E. J. Topol, and A. M. Lincoff Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention Circulation, November 9, 1999; 100(19): 1977 - 1982. [Abstract] [Full Text] [PDF]
|
|